Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Predicted Market Size Trajectory For The Oncology Companion Diagnostics Market From 2025 To 2034?
The oncology companion diagnostics market size has shown swift expansion in recent years. It is anticipated to increase from $3.35 billion in 2024 to $3.79 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.2%. The past growth can be attributed to several factors, including the increasing cases of adverse drug reactions, a rising demand for comprehensive genomic testing, the growing global incidence of cancer, the expanding need for targeted therapy, and an increasing number of clinical trials.
The market for oncology companion diagnostics is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $5.96 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.0%. Several factors contribute to this projected growth, including the growing significance of personalized medicine, a rise in diagnostic testing, a heightened emphasis on individualized cancer treatments, escalating healthcare spending, and an increase in both cancer prevalence and public awareness. Key trends expected during this period encompass progress in diagnostic technologies, the adoption of next-generation sequencing (NGS), the incorporation of artificial intelligence (AI), innovations in liquid biopsy technologies, the creation of point-of-care companion diagnostic instruments, and novel testing approaches.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15623&type=smp
Which Industry Drivers Are Expected To Accelerate The Oncology Companion Diagnostics Market From 2025 To 2029?
The oncology companion diagnostics market is set to experience growth driven by an expected increase in cancer cases. Cancer refers to a intricate group of conditions where abnormal cells in the body proliferate and disseminate uncontrollably. The escalation in cancer cases can be attributed to evolving lifestyle choices, environmental factors, the prevalent issue of obesity, tobacco use, and genetic predispositions. Oncology companion diagnostics contribute significantly to precision medicine approaches in cancer treatment, revolutionizing care by facilitating personalized therapy selection, boosting treatment efficacy, minimizing undesirable side effects, supporting enrollment in clinical trials, and improving monitoring of treatment. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, around 20 million new cases and 9.7 million cancer-related deaths were recorded annually in 2022, and projections suggest that by 2040, there would be 15.3 million deaths and 29.9 million new cases per year. Consequently, the rising incidence of cancer cases acts as a primary catalyst for the oncology companion diagnostics market.
What Are The Major Segments Identified In The Oncology Companion Diagnostics Market?
The oncology companion diagnosticsmarket covered in this report is segmented –
1) By Product: Instrument; Consumables; Software
2) By Disease Type: Melanoma; Breast Cancer; Colorectal Cancer; Leukemia; Prostate Cancer; Other Disease Types
3) By Technology: Immunohistochemistry (IHC); In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH); Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
4) By End User: Hospital; Pathology Or Diagnostic Laboratory; Academic Medical Center; Other End-Users
Subsegments:
1) By Instrument: Polymerase Chain Reaction (Pcr) Instruments; Next-Generation Sequencing (Ngs) Systems; Immunohistochemistry (Ihc) Instruments; Fluorescence In Situ Hybridization (Fish) Instruments; Microarray Platforms
2) By Consumables: Reagents And Kits (Dna Or Rna Extraction Kits, Pcr Reagents); Biopsy Needles; Testing Slides And Chips; Control And Calibration Samples
3) By Software: Data Analysis Software; Bioinformatics Software ( For Gene Expression Analysis); Companion Diagnostic Decision Support Software; Clinical Workflow Management Software
How Are Trends Influencing The Oncology Companion Diagnostics Market?
Leading companies in the oncology companion diagnostics market are focused on creating advanced products, such as in vitro diagnostic tests, to sustain their standing. In vitro diagnostic tests, frequently referred to as IVD tests, are clinical analyses performed on human body samples, including blood or tissue, outside the body in a controlled laboratory setting. For instance, in May 2022, Illumina Inc., a US-based biotechnology company, unveiled a new pan-cancer companion diagnostic (CDx) indication for the in-vitro diagnostic TruSight Oncology (TSO) Comprehensive (EU) test. This diagnostic test generates a comprehensive tumor profile by evaluating multiple tumor genes and biomarkers, allowing healthcare professionals to make informed choices about targeted therapy for cancer patients with solid malignant neoplasms. The test supplies critical information, such as the tumor mutational burden (TMB) score and microsatellite instability (MSI) status, thereby elevating the accuracy and effectiveness of treatment approaches.
Who Are The Key Multinational Companies Dominating The Oncology Companion Diagnostics Market?
Major companies operating in the oncology companion diagnostics market are F. Hoffmann-La Roche AG, Bayer Diagnostic, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, BGI Genomics Co. Ltd., Natera Inc., Myriad Genetics Inc., ARUP Laboratories, NeoGenomics Laboratories Inc., Guardant Health, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Invivoscribe Inc., Pillar Biosciences Inc.
Download The Full Report For Exclusive Market Findings:
Which Geographies Are Emerging As Strong Markets For The Oncology Companion Diagnostics Industry?
North America was the largest region in the oncology companion diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Oncology Companion Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=15623&type=smp
Browse Through More Reports Similar to the Global Oncology Companion Diagnostics Market 2025, By The Business Research Company
Oncology Biosimilar Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Interventional Oncology Devices Global Market Report 2025
Clinical Oncology Next Generation Sequencing Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
